REFERENCES
- McGuire WP, Hoskins WJ, Brady ME, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1–6.
- Kerry, Cadman, E. Pulmonary metastases in ovarian cancer. Cancer 1985; 56: 1209–1213.
- Reed E, Zerbe C, Brawley O, Bicher A, Steinberg S. Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988. Am J Clin Oncol 2000; 23: 107–116.
- Pavlakis G, Mountzios G, Terpos E, Leivaditou A, Papadopoulos G, Papasavas P. Recurrent ovarian cancer metastatic to the sternum, costae and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature. Intl Gynecol Cancer 2006; 16: 299–303.
- Sahdev A, Hughes JH, Barwick T, Rockall AG, Gallagher CJ, Reznek RH. Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol 2007; 48:1038–1044.
- Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106: 1933–1939.
- G. J. Rustin, M. E. van der Burg, on behalf of MRC and EORTC collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC 0V05/EORTC 55955 trials). J ain Oncol 2009; 27:18s.